Chapter title |
Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas
|
---|---|
Chapter number | 17 |
Book title |
Retinal Gene Therapy
|
Published in |
Methods in molecular biology, January 2018
|
DOI | 10.1007/978-1-4939-7522-8_17 |
Pubmed ID | |
Book ISBNs |
978-1-4939-7521-1, 978-1-4939-7522-8
|
Authors |
Timothy P. Day, Leah C. Byrne, John G. Flannery, David V. Schaffer, Day, Timothy P., Byrne, Leah C., Flannery, John G., Schaffer, David V. |
Abstract |
Adeno-associated virus (AAV) has shown promise as a therapeutic gene delivery vector for inherited retinal degenerations in both preclinical disease models and human clinical trials. The retinas of nonhuman primates (NHPs) share many anatomical similarities to humans and are an important model for evaluating AAV gene delivery. Recent evidence has shown that preexisting immunity in the form of neutralizing antibodies (NABs) in NHPs strongly correlates with weak or lack of AAV transduction in the retina when administered intravitreally, work with translational implications. This necessitates prescreening of NHPs before intravitreal delivery of AAV. In this chapter, we describe a method for screening NHP serum for preexisting NABs. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 18 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Unspecified | 2 | 11% |
Student > Ph. D. Student | 2 | 11% |
Student > Postgraduate | 2 | 11% |
Professor | 2 | 11% |
Student > Doctoral Student | 1 | 6% |
Other | 2 | 11% |
Unknown | 7 | 39% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 4 | 22% |
Unspecified | 2 | 11% |
Medicine and Dentistry | 2 | 11% |
Agricultural and Biological Sciences | 1 | 6% |
Engineering | 1 | 6% |
Other | 0 | 0% |
Unknown | 8 | 44% |